Dutch Pharming Group N.V. was profitable at the net level in every quarter and for the year as a whole, with the total net profit for the year ended at €25.0 million, representing a net margin of 19% and well ahead of analysts’ forecasts.
CEO Sijmen de Vries said 2018 was an exciting year for Pharming. De Vries noted the company built on the strong foundations of the successful re-launch of Ruconest, in acute attacks of hereditary angioedema, in the USA in 2017, continuing product sales growth from €88.7 million in 2017 to €134.3 million in 2018, an increase of 51%.
“As well as strong growth in the USA, we continued to develop Ruconest in all key markets. In Europe, direct sales grew well during the year, particularly in the major markets of Western Europe, resulting in strong gains in France and the UK and continued growth in Germany, Austria and the Netherlands,”de Vries said.